Health and wellness are key components to any thriving civilization. Unlike other sectors of the market, healthcare is considered to be one of the more conservative areas to invest because demand for health services does not diminish based on economic outlook. If a recession hit the global economy tomorrow, people will still need to visit primary care professionals, hospitals, pharmacies, clinics, therapists, etc.
However, do not let the term “conservative” fool you into thinking “low growth.” Typically, conservative areas of the market tend to be focused on providing support from losses experienced in the overall market. For example, U.S. Treasury bonds and protective put options are just two examples of traditional conservative investments that help an investor “hedge” against losses in the broader market.
Healthcare is a different beast all together. While healthcare is seen as low-risk compared to highly-cyclical aspects of the market, its growth outlook appears to be quite healthy.
According to the 2018 Global Life Sciences Outlook report by Deloitte, global healthcare spending is estimated to reach $8.7 trillion by 2020 compared to $7 trillion in 2015. The market research firm notes that aging and increasing populations, expanding emerging markets, medical technology advancements, and rising labor costs are the main culprits behind the projected rise in health spending.
One company preparing to benefit from the upbeat healthcare outlook is Innovest Global, Inc. (OTC Pink: IVST).
Medical Advancements Causing People To Live Longer, 11.50% Of World Population Now Over 65 Years Old
As technological capabilities continue to progress, medical treatments are becoming more effective. As a result, around 656 million people, or 11.50% of the total world population, is now aged 65 years or older. However, while people are generally living longer today, ailments and diseases are surprisingly on the rise.
According to Deloitte, diabetes is forecast to affect around 642 million people by 2040 due to rapid urbanization, diet changes, increasingly sedentary lifestyles, and rising obesity rates. Rising ailments and diseases are no doubt the cause behind the projected growth in pharmaceutical sales, which are estimated to reach $1.06 trillion globally by 2022.
On a positive note, medical technology (Medtech) and orphan drugs are projected to soar into the next decade. The market research firm sees medtech reaching $521.9 billion by 2022, with in virtro diagnostics estimated to be the largest segment.
Furthermore, technology breakthroughs are allowing medical researchers to develop more life-saving orphan drugs. Orphan drugs are pharmaceutical compounds that are designed to treat a rare disease or medical ailment. Over the next five years, market researchers believe we could see the entire orphan drug market double.
IVST: LOI To Acquire 20% Stake In Brain Cancer Vaccine Developer, StemVax Therapeutics
Recently, Innovest Global, Inc. (OTC Pink: IVST) announced that it has entered into a Letter of Intent to acquire a 20% stake in StemVax Therapeutics, a translational biotechnology company that is working on developing a brain cancer vaccine. Specifically, the vaccine will focus on treatment of glioblastomas, the same form of brain cancer that is affecting Arizona Senator John McCain.
Once the acquisition closes this Spring, Innovest Global, Inc. (OTC Pink: IVST) will officially launch its newly developed Biotech & Health Sciences division, which will be led by world-renowned neuroscientist, Dr. Dwain Morris-Irvin. Interestingly enough, Dr. Morris-Irvin is also the founder and CEO of StemVax Therapeutics, making the acquisition a perfect fit into the Innovest Global, Inc. (OTC Pink: IVST) holding company family.
In other news, Innovest Global, Inc. (OTC Pink: IVST) recently announced that it has engaged the PCAOB auditing firm, NMS, Inc., to complete a two-year audit of the company’s financials. This is company’s first step in its mission to begin uplisting to higher exchanges, such as the OTCQX and eventually the NASDAQ or NYSE. NMS, Inc. has a 30-year track record of success and features 40 employees.
Click Here To See Innovest Global, Inc. (OTC Pink: IVST) Featured On Our Inaugural Episode Of Spotlight Growth Live
Management is pleased to announce that it has begun the second quarter with baseline quarterly revenues of around $800,000, just from its Commercial & Industrial Energy division alone. This does not include the Biotech & Health Sciences division which is estimated to formally launch this quarter.
Outside of its existing holdings, Innovest Global, Inc. (OTC Pink: IVST) maintains a bountiful acquisition pipeline, which now features fourteen companies. Eleven of the fourteen companies within the pipeline are already generating “greater annual revenue than Innovest’s current base, showing the business plan advancing into incrementally larger transactions.
Overall, Innovest Global, Inc. (OTC Pink: IVST) is firing on all cylinders. Management is continuing to execute its business and growth plans right on schedule, as the Biotech & Health Sciences division prepares to get underway. Furthermore, the company’s Commercial & Industrial Energy division continues to be a “cash cow” for the company, as baseline quarterly revenues now reach $800,000. Further massive acquisitions are within the Innovest Global, Inc. (OTC Pink: IVST)’s existing pipeline and, if executed, could propel the company into the stratosphere.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/
